Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS — Stella

Home/Multiple Sclerosis/

View on ClinicalTrials.gov

Recruiting

Back to Multiple Sclerosis trials

Phase 3 — Large-scale testing across thousands of people, comparing the new treatment against current standard treatments.

Trial locations(1 site)

Netherlands

Amsterdam UMC, location VUmc, Amsterdam

Key details

Phase

Large-scale testing

Sponsor

Amsterdam UMC, location VUmc

Collaborators

Stichting Treatmeds

Enrollment target

~200 participants

Started

April 2023

Primary completion

May 2027

Age range

18 Years and older

Last updated April 2023

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.